Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.0000 (0.93%) ($11.8700 - $12.0800) on Thu. Jun. 27, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.89% (three month average) | RSI | 53 | Latest Price | $12.0000(0.93%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.7% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(60%) XBI(56%) IWO(55%) IWM(52%) IWC(50%) | Factors Impacting FOLD price | FOLD will decline at least -1.445% in a week (0% probabilities). VIXM(-32%) VXX(-19%) TLT(-14%) IFRA(-9%) TIP(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.445% (StdDev 2.89%) | Hourly BBV | 0 () | Intraday Trend | 0.7% | | | |
|
5 Day Moving Average | $12.07(-0.58%) | 10 Day Moving Average | $12.11(-0.91%) | 20 Day Moving Average | $11.88(1.01%) | To recent high | -16.7% | To recent low | 9.5% | Market Cap | $3.099b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |